Characteristics of L-citrulline transport through blood-brain barrier in the brain capillary endothelial cell line (TR-BBB cells)

Kyeong-Eun Lee and Young-Sook Kang*

Abstract

Background: L-Citrulline is a neutral amino acid and a major precursor of L-arginine in the nitric oxide (NO) cycle. Recently, it has been reported that L-citrulline prevents neuronal cell death and protects cerebrovascular injury, therefore, L-citrulline may have a neuroprotective effect to improve cerebrovascular dysfunction. Therefore, we aimed to clarify the brain transport mechanism of L-citrulline through blood-brain barrier (BBB) using the conditionally immortalized rat brain capillary endothelial cell line (TR-BBB cells), as an in vitro model of the BBB.

Methods: The uptake study of [14C] L-citrulline, quantitative real-time polymerase chain reaction (PCR) analysis, and rLAT1, system b0,+, and CAT1 small interfering RNA study were performed in TR-BBB cells.

Results: The uptake of [14C] L-citrulline was a time-dependent, but ion-independent manner in TR-BBB cells. The transport process involved two saturable components with a Michaelis–Menten constant of 30.9 ± 1.0 μM (Km1) and 1.69 ± 0.43 mM (Km2). The uptake of [14C] L-citrulline in TR-BBB cells was significantly inhibited by neutral and cationic amino acids, but not by anionic amino acids. In addition, [14C]L-citrulline uptake in the cells was markedly inhibited by 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), which is the inhibitor of the large neutral amino acid transporter 1 (LAT1), B0, B0,+ and harmaline, the inhibitor of system b0,+. Gabapentin and L-dopa as the substrates of LAT1 competitively inhibited the uptake of [14C] L-citrulline. IC50 values for L-dopa, gabapentin, L-phenylalanine and L-arginine were 501 μM, 223 μM, 68.9 μM and 33.4 mM, respectively. The expression of mRNA for LAT1 was predominantly increased 187-fold in comparison with that of system b0,+. In the studies of LAT1, system b0,+ and CAT1 knockdown via siRNA transfection into TR-BBB cells, the transcript level of LAT1 and [14C] L-citrulline uptake by LAT1 siRNA were significantly reduced compared with those by control siRNA in TR-BBB cells.

Conclusions: Our results suggest that transport of L-citrulline is mainly mediated by LAT1 in TR-BBB cells. Delivery strategy for LAT1-mediated transport and supply of L-citrulline to the brain may serve as therapeutic approaches to improve its neuroprotective effect in patients with cerebrovascular disease.

Keywords: L-Citrulline, Blood-brain barrier (BBB), Large amino acid transporter 1 (LAT1), Nitric oxide (NO), L-Dopa-Gabapentin

Background

L-Citrulline is a neutral and non-protein amino acid which was first identified in the juice of watermelon, Citrullus vulgaris Schrad [1]. L-Citrulline has usually been known as a metabolic intermediate in the urea cycle. Recently, L-citrulline has been investigated with a focus on L-citrulline as a product of the nitric oxide (NO) cycle and as a precursor for arginine by nitric oxide synthase (NOS) [2, 3]. L-Citrulline is converted to L-arginine by argininosuccinate synthase and lyase in the NO cycle [4]. As L-arginine can be recycled from L-citrulline through the NO cycle in some cells such as intestinal cells [5], L-citrulline plays an important role in NO metabolism and regulation [3].

In the central nervous system (CNS), NO plays an important role in the cell death or survival mechanisms in brain cells [6, 7]. Neuronal NOS (nNOS) is expressed in neuronal tissues such as neurons and synaptic spines.
Inducible NOS (iNOS) can be synthesized by pro-inflammatory cytokines or endotoxin. Endothelial NOS (eNOS) is found in endothelial cells [8]. In general, NO produced by eNOS regulates numerous physiological actions and is neuroprotective to the brain, whereas the comparatively large amount of NO generated by iNOS evokes oxidative stress and is clearly neurotoxic to the brain [9]. nNOS is involved in modulating physiological functions such as learning, memory, and neurogenesis, and pathological condition in the CNS such as Parkinson’s disease and Alzheimer’s disease [10]. Abnormal elevation of NO causes brain damage following cerebral ischemia during the subacute phase [11, 12]. Recently, the neuroprotective effect of L-citrulline on CNS disorders such as brain ischemia has been investigated [13]. Previous studies have shown that L-citrulline not only prevented neuronal cell death but it also prevented capillary loss in the hippocampal region by cerebral ischemia. The cerebrovascular protective effect of L-citrulline was associated with the restoration of endothelial nitric oxide synthase (eNOS) expression in the hippocampus [13]. Thus, L-citrulline administration may offer a potential therapeutic strategy not only for patients with impaired arginine metabolism and deficiencies but also for controlling NO metabolism disorders and cell death in the CNS [3, 13].

Neutral amino acids such as L-citrulline are transported through cell membranes by several distinct transport systems in different cell types, including macrophages [14], rat aortic smooth muscle cells [15], neural cells [16], bovine aortic endothelial cells [17], and intestinal cells [2]. Systems B0 and B0,+, as Na+-dependent transport systems for neutral amino acids, have been identified [18]. Systems B0,+, L, and y’L are Na+-independent transport systems for neutral amino acids in various cell types [19]. In addition, systems B0,+ and B0,K, have also been found to be related to transport of cationic amino acids in human intestinal epithelial cells [2, 19] and proximal tubular cells [20], respectively. System y’L, encoded by y’LAT1 and y’LAT2, mediates the Na+-dependent transport of neutral amino acids as well as the Na+-independent transport of cationic amino acids [18]. However, the characteristics of the L-citrulline transport system across the blood-brain barrier (BBB) are still unclear. Therefore, the purpose of this study was to characterize the transport system for L-citrulline through BBB using the conditionally immortalized rat brain capillary endothelial cell line (TR-BBB cells), as an in vitro model of the BBB [21].

**Methods**

**Materials**

[^14C]L-Citrulline ([^14C] L-citrulline, 56.3 mCi/mmol) was purchased from PerkinElmer (Waltham, Massachusetts, USA). L-dopa and Donepezil hydrochloride were provided by Jeil Co. and Daewoong Co. (Seoul, Korea), respectively. Quinidine was obtained from Tokyo Kasei Kogyo Co. (Tokyo, Japan). L-Amino acids were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). All other chemicals and reagents were commercial products of reagent grade.

**Cell culture**

The TR-BBB cells established from transgenic rats harboring the temperature-sensitive simian virus 40 large T-antigen, an in vitro BBB model, were cultured at 33 °C as described previously [21]. TR-BBB cells were received from Professor Tetsuya Terasaki (Tohoku University, Japan) and were cultured with Dulbecco’s modified Eagle’s medium (Invitrogen, San Diego, CA), supplemented with 10% fetal bovine serum, 100 μg/mL penicillin, 100 μg/mL streptomycin (Invitrogen, San Diego, CA) and 15 μg/L endothelial cell growth factor (Roche, Mannheim, Germany) at 33 °C in a humidified atmosphere of 5% CO2/air. On rat tail collagen type I-coated 24 well culture plates (IWAKI, Tokyo, Japan) initial seeding was carried out at 1 × 10^5 cells/well for the uptake study. After incubation for 2 days at 33 °C, the cultures became confluent and then they were used in the transport study. L-Citrulline free medium was used all experiments except for experiments on saturation kinetics of[^14C]L-citrulline uptake (Fig. 2), Lineweaver-Burk plots for[^14C]L-citrulline uptake (Fig. 4), or inhibitory effect of L-amino acids as a control (Table 2).

**Uptake study in TR-BBB cells**

The[^14C] L-citrulline uptake study was performed according to the previous report [22]. Briefly, extracellular fluid (ECF) buffer containing[^14C]L-citrulline (44.4 μM) in the presence or absence of unlabeled inhibitors was added to the TR-BBB cells and then incubated at pH 7.4 and 37 °C for the designated time (5 min). Uptake was terminated by the addition of ice-cold ECF buffer. A Na + free transport medium was prepared by using LiCl, choline chloride, sodium gluconate and KHCO3 instead of NaCl and NaHCO3, respectively. The cells were then solubilized by incubation overnight in 750 μL of 1 N NaOH at room temperature, and the measurement of radioactivity was performed in a liquid scintillation counter (LS6500; Beckman, Fullerton, CA). Cell to medium ratio (μL/mg protein) was calculated as follows: the radioactivity (dpm/μL) in the sample per milligram cell protein (dpm/mg protein).

**Data analysis**

For kinetic studies, the Michaelis-Menten constant (Km) and the maximum uptake rate (Vmax) of[^14C] L-citrulline were estimated from Eq. (1):
\[ V = \frac{V_{\text{max}} \cdot C}{(K_m + C)} \]  

(1)

Where \( V \) and \( C \) are the initial uptake rate of \(^{14}\text{C}\) L-citrulline at 5 min and the concentration of L-citrulline, and \( V_{\text{max}} \) is the maximum uptake rate for the saturable component.

To analyze the competitive nature of L-dopa and gabapentin for \(^{14}\text{C}\) L-citrulline uptake, Lineweaver-Burk plots were generated. The inhibitory constant \((K_i)\) was calculated from Eq. (2):

\[ V = \frac{V_{\text{max}} \cdot C}{[K_m \cdot (1 + I/K_i) + C]} \]  

(2)

where \( I \) corresponds to the concentration of L-dopa or gabapentin, respectively.

Statistical analyses were carried out by one-way ANOVA with Dunnett’s post-hoc test.

Preparation of rat cerebrum
An animal experiment was approved by the Committee of the Ethics of Animal Experimentation of Sookmyung Women’s University (SMWU-IACUC-1405-009). Three male Sprague-Dawley (SD) rats (Koatech, Gyeonggi-do, Korea) at aged of 8 weeks (250–350 g) were anesthetized intramuscularly with 100 mg/kg ketamine (Yuhan, Seoul, Korea). After SD rat was anesthetized, the rat was decapitated and the cerebrum was immediately removed. The cerebrum was homogenized with 5 ml syringe (18 gage needle). These homogenized cerebrum tissues (30 mg) were used to isolate total RNA for real-time PCR analysis.

Real-time PCR analysis
Total RNA was isolated from cultured TR-BBB cells and rat cerebrum tissues by using the RNeasy Mini Kit from Qiagen (Qiagen, Valencia, CA) according the manufacturer’s instructions. Total RNA (2 µg) was reverse-transcribed by using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies). Real-time PCR was performed in 48-well plates with the StepOne apparatus (Applied Biosystems, Life Technologies) using the MGB Taqman probe assay. Probes for LAT1, system b0,+ and CAT1 were purchased from Applied Biosystems (Rn00569313_m1, Rn00588400_m1, Rn00565399_m1 and Rn99999916_s1, respectively). Each reaction contained 5 µl Taqman Universal PCR Mastermix in a total volume of 10 µl, and 1 µl cDNA was added to the reaction. Real-time PCR reactions were performed at 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. The results of the analysis were calculated in relation to the GAPDH product, and the results were calculated according to, and expressed by an equation \((2^{\Delta\Delta Ct})\) that gives the amount of target, normalized to an endogenous reference and relative to a calibrator. Ct is the threshold cycle for target amplification (Livak and Schmittgen 2001).

rLAT1, system b0,+ and CAT1 small interfering RNA and small interfering RNA transfection
Transient knockdown of rLAT1, system b0,+ and CAT1 in TR-BBB cells was achieved by using small interfering RNA (siRNA) from Dharmacon, GE (Landsmeer, Netherlands). rLAT1, system b0,+ and CAT1 were targeted with a SMART pool containing 4 different siRNAs and with each single siRNA individually. The final concentration of siRNA was 200 nM. The rLAT1, system b0,+ and CAT1 or control siRNA was delivered individually into TR-BBB cells by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Cells were used for quantitative real-time PCR and \(^{14}\text{C}\) L-citrulline uptake was analyzed at 48 h after the initiation of transfection.

Results
Characterization of \(^{14}\text{C}\) L-citrulline transport by TR-BBB cells
To investigate the L-citrulline transport system at the BBB, we first performed the \(^{14}\text{C}\) L-citrulline uptake study using TR-BBB cells, as an in vitro model of the BBB. The uptake of \(^{14}\text{C}\) L-citrulline was increased in a time-dependent manner and it was linear for 5 min (Fig. 1). Therefore, \(^{14}\text{C}\) L-citrulline uptake by TR-BBB cells was assessed at 5 min in the subsequent kinetic and inhibition studies. In addition, \(^{14}\text{C}\) L-citrulline uptake by TR-BBB cells showed no significant difference in the absence of Na\(^+\) or Cl\(^-\) in the uptake buffer (Table 1). These results suggested that the transport of L-citrulline in TR-BBB cells was mediated by a sodium- and chloride-independent transporter.

![Time-course of \(^{14}\text{C}\) L-citrulline uptake by TR-BBB cells](image-url)
To analyze the kinetics of [14C]L-citrulline uptake by TR-BBB cells, we examined the concentration dependence of [14C]L-citrulline uptake. The transport of [14C]L-citrulline was saturable (Fig. 2). Kinetic analysis provided two components with a $K_m1$ value of 30.9 ± 1.0 μM and a $K_m2$ value of 1.69 ± 0.43 mM, which fitted into the Michaelis-Menten equation. In addition, the $V_{max1}$ value was 185 nmol/mg/min, and the $V_{max2}$ value was 3.19 μmol/mg/min. The Eadie-Hofstee plot for [14C]L-citrulline uptake showed two straight lines, indicating two saturable processes. These data implied that L-citrulline transport in TR-BBB cells involved carrier mediated transport system.

### Effect of various L-amino acids on [14C]L-citrulline transport by TR-BBB cells

To examine the L-citrulline transport mechanism related to L-amino acids in TR-BBB cells, [14C]L-citrulline uptake was measured in the presence of 2 ~ 20 mM unlabeled L-amino acids. The uptake of [14C]L-citrulline in TR-BBB cells was strongly inhibited by various neutral amino acids such as L-phenylalanine and it was significantly inhibited by cationic amino acids such as L-arginine and L-lysine. Substrates of system ASC such as L-alanine, L-serine and L-cysteine also significantly inhibited [14C]L-citrulline uptake in the cells. In contrast, anionic amino acids including L-glutamate and L-aspartate did not inhibit the uptake in TR-BBB cells (Table 2). These results indicated that L-citrulline transport in TR-BBB cells is related to neutral and cationic amino acid transport.

### Effect of inhibitors of several transporters on [14C]L-citrulline transport by TR-BBB cells

To identify the transporters involved in L-citrulline transport in TR-BBB cells, an inhibition study assessing the effect of several transporter inhibitors on [14C]L-citrulline uptake was conducted. [14C]L-citrulline uptake was markedly inhibited by BCH, which is the inhibitor of systems L, B$^0$ and B$^{0,+}$. In addition, harmaline, the inhibitor of system b$^{0,+}$ significantly reduced the uptake to 39% of the control. However, there was no inhibition effect of L-methylmaleimide, homoarginine, and N-(methylamino) isobutyric acid (MeAIB), which are the inhibitors of systems y$^+$L, y$^+$, and A, respectively (Table 3). These results implied that L-citrulline transport in TR-BBB cells is related to systems L and b$^{0,+}$.

### Table 1: Ion-dependence of [14C]L-citrulline uptake in TR-BBB cells

| Substrate               | Uptake of [14C]L-citrulline (% of control) |
|-------------------------|--------------------------------------------|
| Control                 | 100 ± 1.9                                  |
| Choline Chloride        | 83.3 ± 5.7                                 |
| LiCl                    | 116.2 ± 5.2                                |
| Sodium gluconate        | 103.9 ± 6.8                                |

[14C]L-Citrulline uptake by TR-BBB cells was performed at pH 7.4 and 37 °C for 5 min in the presence or absence of sodium and/or chloride. Each value represents the mean ± S.E.M. ($n = 3–4$)
Inhibition of \([^{14}\text{C}]\) L-citrulline uptake by several drugs in TR-BBB cells

To investigate the transport effect between L-citrulline and several drugs in TR-BBB cells, we conducted the inhibition study for \([^{14}\text{C}]\) L-citrulline uptake in TR-BBB cells. L-dopa and gabapentin, which are the substrates of system L, strongly inhibited the uptake of \([^{14}\text{C}]\) L-citrulline. In addition, verapamil and quinidine significantly inhibited the uptake of L-citrulline. In contrast, donepezil, tacrine, dopamine and riluzole had no effect on \([^{14}\text{C}]\) L-citrulline uptake in TR-BBB cells.

Inhibitory effect of several L-amino acids and drugs on \([^{14}\text{C}]\) L-citrulline transport by TR-BBB cells

The dose-response relationship for the inhibition of \([^{14}\text{C}]\) L-citrulline uptake by L-phenylalanine, L-arginine, L-dopa and gabapentin in TR-BBB cells is given in Fig. 3. The IC\(_{50}\) values for L-dopa, gabapentin, L-phenylalanine and L-arginine were 501 \(\mu\)M, 223 \(\mu\)M, 68.9 \(\mu\)M and 33.4 \(\mu\)M, respectively.

Lineweaver–Burk plot for L-citrulline uptake in TR-BBB cells showed the inhibitory effect of L-dopa and gabapentin (Fig. 4). \([^{14}\text{C}]\) L-Citrulline uptake in TR-BBB cells was competitively inhibited by L-dopa and gabapentin with \(K_i\) values of 486 \(\mu\)M and 679 \(\mu\)M, respectively.

Expression of mRNA for LAT1 and system b\(_{0,+}\) in TR-BBB cells

To evaluate which transport system was mainly used for L-citrulline transport in TR-BBB cells, we performed real-time PCR analysis of the mRNA expression of LAT1 and system b\(_{0,+}\) in TR-BBB cells and rat whole brain. The mRNA expression level of LAT1 was about 187 fold higher compared with system b\(_{0,+}\) in TR-BBB cells. But, the mRNA expression level of LAT1 was 57.4 fold higher in comparison with system b\(_{0,+}\) in rat cerebrum (Fig. 5). These results suggest that LAT1 is mainly involved in L-citrulline transport in TR-BBB cells.

Effects of rLAT1, system b\(_{0,+}\) and CAT1 siRNA on transcript levels of rLAT1, system b\(_{0,+}\) and CAT1 and \([^{14}\text{C}]\) L-citrulline uptake in TR-BBB cells

In order to confirm whether LAT1, system b\(_{0,+}\) and CAT1 were involved in L-citrulline transport in TR-BBB cells, we performed rLAT1, system b\(_{0,+}\) and CAT1 knockdown by siRNA transfection into TR-BBB cells. The transcript levels of each mRNA and \([^{14}\text{C}]\) L-citrulline uptake were determined 48 h after siRNA transfection into TR-BBB cells. The transcript levels of rLAT1, system b\(_{0,+}\) and CAT1 were significantly decreased by 60, 28 and 65%, respectively, compared to that of control siRNA on quantitative real-time PCR analysis (Fig. 6a). On the other hand, \([^{14}\text{C}]\) L-citrulline uptake in TR-BBB cells transfected only with rLAT1 siRNA was significantly reduced by 34% compared with that of control siRNA (Fig. 6b), suggesting that LAT1 is mainly involved in \([^{14}\text{C}]\) L-citrulline uptake by TR-BBB cells.

Discussion

The purpose of this study was to investigate the transport characteristics of L-citrulline with use of various compounds and drugs at the BBB. Brain endothelial cells are the main component of the BBB and they express many

**Table 2** Effect of L-amino acids on uptake of \([^{14}\text{C}]\) L-citrulline in TR-BBB cells

| Substrate     | Concentration (mM) | Uptake of \([^{14}\text{C}]\) L-citrulline (% of control) |
|---------------|--------------------|----------------------------------------------------------|
| Control       |                    | 100 ± 1.3                                                 |
| L-Citrulline  | 2                  | 36.0 ± 2.1 ***                                           |
| L-Valine      | 2                  | 31.5 ± 1.4 ***                                           |
| L-Leucine     | 2                  | 49.4 ± 5.8 ***                                           |
|               | 20                 | 17.2 ± 3.9 ***                                           |
| L-Phenylalanine| 2                  | 13.7 ± 1.8 ***                                           |
| L-Glutamine   | 2                  | 37.5 ± 1.3 ***                                           |
| L-Alanine     | 2                  | 73.0 ± 6.4 **                                            |
| L-Serine      | 2                  | 79.7 ± 2.5                                              |
| L-Cysteine    | 2                  | 48.4 ± 2.6 ***                                           |
| L-Arginine    | 2                  | 59.9 ± 6.6 **                                            |
|               | 20                 | 53.2 ± 4.4 ***                                           |
| L-Lysine      | 2                  | 74.5 ± 9.0                                              |
|               | 20                 | 66.78 ± 2.1 *                                            |
| L-Glutamate   | 2                  | 102.8 ± 7.8                                              |
| L-Aspartate   | 2                  | 101.5 ± 8.6                                              |

\([^{14}\text{C}]\) L-Citrulline uptake by TR-BBB cells was performed at pH 7.4 and 37 °C for 5 min in the presence or absence of 2–20 mM L-amino acids. Each value represents the mean ± S.E.M. (\(n = 3–4\)). *\(p < 0.05\), **\(p < 0.01\), ***\(p < 0.001\); significantly different from control

**Table 3** Effect of several transporter inhibitors on uptake of \([^{14}\text{C}]\) L-citrulline in TR-BBB cells

| Substrate     | Concentration (mM) | Uptake of \([^{14}\text{C}]\) L-citrulline (% of control) |
|---------------|--------------------|----------------------------------------------------------|
| Control       |                    | 100 ± 1.3                                                 |
| BCH           | 2                  | 25.3 ± 4.4 ***                                           |
|               | 20                 | 28.1 ± 11.6 ***                                          |
| Harmaline     | 2                  | 61.0 ± 10.5 **                                           |
| Methylmaleimide| 2                | 103.2 ± 10.1                                             |
| Homoarginine  | 2                  | 95.08 ± 13.8                                             |
| MeAIB         | 2                  | 99.8 ± 6.3                                               |

\([^{14}\text{C}]\) L-Citrulline uptake by TR-BBB cells was performed at pH 7.4 and 37 °C for 5 min in the presence or absence of 2–20 mM inhibitors. Each value represents the mean ± S.E.M. (\(n = 3–4\)). **\(p < 0.01\), ***\(p < 0.001\); significantly different from control
transporters for substances, such as drugs, chemical compounds, amino acids, and proteins [23]. Due to the different structures and properties of substrates or drugs, it is important to understand the transport system in order to regulate their permeability from blood to brain. In the present study, we used TR-BBB cells which were established as an in vitro model of the BBB by Hosoya et al. [21]. 

L-Citrulline transport has been reported to be mediated by Na\(^+\) independent and/or Na\(^+\) dependent transport system in different cell types such as rat intestinal Caco-2 cells, macrophages, etc. [19]. Our results showed that the uptake of \(^{14}\text{C}\)L-citrulline was a time-dependent (Fig. 1), but Na\(^+\) and Cl\(^-\)-independent (Table 1) transport occurred in TR-BBB cells. In the kinetic uptake

Fig. 3 Dose-response relationship for the inhibition of \(^{14}\text{C}\)L-citrulline uptake by several L-amino acids and drugs. Uptake of \(^{14}\text{C}\)L-citrulline was measured in TR-BBB cells with 5 min incubation in the presence of 0–20 mM unlabeled L-phenylalanine (open circle) and L-arginine (closed triangle), 0–5 mM L-dopa (open triangle) and gabapentin (close circle) at pH 7.4 and 37 °C. The data represent the mean ± S.E.M. (n = 3–4)

Fig. 4 Lineweaver-Burk plots for \(^{14}\text{C}\)L-citrulline uptake by TR-BBB cells showing competitive inhibition by L-dopa and gabapentin. \(^{14}\text{C}\)L-citrulline (44.4 μM) uptake was performed in the presence of 300 μM L-dopa (close circle) and 300 μM gabapentin (close triangle) or in their absence (open circle) in TR-BBB cells at pH 7.4 and 37 °C for 5 min. The data represents the mean ± S.E.M. (n = 3–4)
study of $[^{14}\text{C}]$-l-citrulline, l-citrulline was transported by two saturable carrier-mediated transport systems (Fig. 2). These data suggested that transport of l-citrulline involves Na$^+$-independent carrier-mediated transport systems in TR-BBB cells. Regarding the interaction of various amino acids with l-citrulline transport in TR-BBB cells, the uptake of $[^{14}\text{C}]$-l-citrulline was strongly inhibited by neutral amino acids and it was significantly inhibited by small neutral amino acids and cationic amino acids (Table 2). However, there were no inhibition effects of several anionic amino acids including l-glutamate and l-aspartate (Table 2). These results were in accordance with the results obtained in HK-2 cells in the previous study by Mitsuoka et al. [20]. System X$\text{AG}^-$ may not be involved in the transport of l-citrulline at the BBB, as l-citrulline is in a zwitterionic state at physiological pH [24]. Thus, these data suggested that l-citrulline transport is mediated by both neutral amino acid and cationic amino acid transport systems. When we investigated the inhibition effect of candidate inhibitors of several transporters on l-citrulline transport in TR-BBB cells, $[^{14}\text{C}]$-l-citrulline uptake was decreased by about 75% with BCH (Table 3). BCH is an amino acid-related compound that has been used as a selective
inhibitor of system L including LAT1 and LAT2 [25, 26]. It has also been reported as the inhibitor of systems B0 and B0+, [27]. However, systems B0 and B0+ are usually related to the Na+−dependent transport system for neutral amino acids [18]. Thus, these results indicated that BCH acted as the inhibitor of system L for L-citrulline transport in TR-BBB cells. In addition, harmaline, which is the inhibitor of system B0+ [27], significantly inhibited the uptake of [14C]L-citrulline by about 40% in the cells (Table 3). These data implied that L-citrulline transport systems in TR-BBB cells may involve systems L and B0+ as Na+-independent transport systems. Previous reports have also mentioned that LAT1 is mainly expressed in bovine brain capillaries [28, 29]. Based on these reports and our results, we performed further studies to compare the mRNA expression of LAT1 with that of system B0+ in TR-BBB cells by quantitative real-time PCR (Fig. 5) in order to investigate which transport system is mostly involved in L-citrulline uptake. We confirmed that the mRNA expression level of LAT1 was predominantly increased by about 187 fold compared with that of system B0+ in TR-BBB cells. Also, LAT1 expression was highly increased by 57 fold in comparison with that of system B0+ in rat cerebrum. Moreover, in the functional study of LAT1 and system B0+ knockdown using siRNA transfection, quantitative real-time PCR results showed that the transcript levels of rLAT1 and system B0+ siRNA were significantly reduced compared with that of control siRNA (Fig. 6a), whereas [14C]L-citrulline uptake by TR-BBB cells transfected with only rLAT1 siRNA was significantly reduced by 34% compared with that of control siRNA (Fig. 6b). Therefore, our finding strongly indicated that LAT1 is mainly involved in L-citrulline transport in TR-BBB cells, even though system B0+ is slightly expressed in the BBB. O’Kane RL et al. have reported that harmaline is an inhibitor of system B0+, [27], but it was not considered to be a specific inhibitor of system B0+ only in TR-BBB cells because harmaline has been reported to interact with numerous receptors as well as ion exchangers and voltage-sensitive channels [30]. In addition, based on our results of the inhibition study with L-arginine (Table 2.), we also confirmed whether the cationic amino acid transporter 1 (CAT1) is involved in L-citrulline transport in TR-BBB cells by performing CAT1 siRNA transfection (Fig. 6). CAT1 has been reported to be the main L-arginine transporter in the BBB [31]. CAT1 transports such basic amino acids, and its expression is concentrated in brain capillaries [32]. The uptake study of [14C]L-citrulline showed that there was no significant reduction by CAT1 siRNA when compared with that by control siRNA in TR-BBB cells (Fig. 6b). These results implied that CAT1 is less relevant for L-citrulline transport in TR-BBB cells.

On the other hand, the K_m values of LAT1 show about 10 ~ 100 μM of high affinity and 1 ~ 10 mM of low affinity in the BBB [28, 33]. Actually, the K_m values of L-citrulline (K_m1 = 30.9 μM and K_m2 = 1.69 mM) in TR-BBB cells were in the similar range as the values of LAT1 in previous studies. L-Arginine significantly inhibited the uptake of [14C]L-citrulline (Table 2) and the IC50 value of L-arginine was 33.4 mM (Fig. 3) in TR-BBB cells. Especially, the reason why co-treatment with L-arginine inhibited the transport of L-citrulline can be considered to be the strong interaction between L-arginine and L-citrulline due to their structural similarity [2]. In our results, the IC50 value of L-arginine was relatively high compared with those of L-phenylalanine, L-dopa and gabapentin. These results implied that L-arginine is transported by a different transport system such as CAT1 and system B0+. Moreover, L-arginine transport may have a negligible effect on L-citrulline transport in clinical conditions due to the high IC50 value with a millimolar (mM) level for L-citrulline in this study. It has been reported that L-citrulline has better absorption and systemic bioavailability than L-arginine [34, 35] and it did not induce osmotic diarrhea at high dosage compared with L-arginine [36]. Also, if there is a different transport system for L-arginine as shown by our results, it can be considered that L-citrulline treatment is a more effective therapeutic method for L-arginine deficiency in clinical conditions. In addition, Shen LJ et al. have reported that argininosuccinate synthase (AS) activity plays a pivotal role in intracellular citrulline-arginine regeneration via eNOS for NO production [37]. Therefore, to elucidate the clinical effect for NO pathway related to L-citrulline transport in the BBB, further studies are remained to measure several parameters in NO pathway such as AS, NOS proteins and NO etc. related to L-citrulline transport in TR-BBB cells.

In the inhibition study between L-citrulline transport and CNS-acting drugs such as donepezil, tacrine, dopamine and riluzole in TR-BBB cells, donepezil and tacrine had no significant inhibition effect on [14C]L-citrulline uptake (Table 4). Donepezil and tacrine, which are AChE inhibitors and have been used as therapeutic agents for Alzheimer’s disease (AD), show a relatively high distribution in the brain [38–40]. These drugs show a competitive inhibition of choline transport via OCT2 in TR-BBB cells [41] and they are transported across the BBB to the brain via the choline transport system, CHT1 [42, 43]. Due to the use of this transport system for donepezil and tacrine in the BBB, it seems that these drugs do not have inhibition effect for L-citrulline transport in TR-BBB cells. We also confirmed that dopamine, riluzole and taurine had no significant effects on [14C]L-citrulline uptake in TR-BBB cells. Dopamine is a neurotransmitter belonging to the family of catecholamines, and it
is a therapeutic agent for Parkinson’s disease (PD) in the brain. In the BBB, dopamine is transported by rat plasma membrane monoamine transporter (rPMAT) in TR-BBB and TR-CSFB cells [44]. Transport of taurine, a beta-amino acid and has neuroprotective effect, which is mediated by TAUT in TR-BBB cells [22]. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) is a neuroprotective drug approved for amyotrophic lateral sclerosis [45] and activates GLT-1 and GLAST to enhance glutamate uptake [46, 47], but there have been poor mechanistic experiments to transport riluzole across the BBB to the brain. L-Citrulline transport is not affected by these two drugs via different transport systems in TR-BBB cells. However, L-dopa, gabapentin, verapamil, and quinidine significantly inhibited the uptake of $[^{14}C]$L-citrulline (Table 4). It has been reported that L-dopa and gabapentin are transported across the BBB by LAT1 [48, 49]. Therefore, we hypothesized that the transport systems for L-citrulline might involve mainly LAT1. The IC$_{50}$ values for L-dopa and gabapentin were 501 μM and 223 μM, respectively (Fig. 3) and they competitively inhibited L-citrulline uptake with 486 μM and 679 μM as the K$_i$ values for L-dopa and gabapentin, respectively in the Lineweaver-Burk plot analysis (Fig. 4). These results indicated that L-citrulline may also be a substrate of LAT1 in TR-BBB cells, as L-dopa and gabapentin compete with L-citrulline for the same binding site on LAT1. However, the maximal plasma concentrations ($C_{\text{max}}$) of L-dopa and gabapentin at steady state were 1~20 μM and 23~80 μM, respectively [50, 51]. These results demonstrated that the K$_i$ values for L-dopa and gabapentin are several times higher than their $C_{\text{max}}$. Therefore, these drugs may not significantly inhibit L-citrulline transport via LAT1 at the BBB in clinical conditions. Kageyama et al. reported that L-dopa is transported by LAT1 in MBEC4 cells [48]. However, there was no inhibition effect on L-dopa transport with cationic amino acids including L-arginine and L-lysine in their study. These results were not in agreement with our results for L-citrulline transport in TR-BBB cells. Therefore, for L-citrulline transport across the BBB, the effects of cationic amino acids, not L-dopa and gabapentin in TR-BBB cells should be further studied. Furthermore, L-citrulline transport across the BBB was also inhibited by CNS-acting drugs such as L-dopa and gabapentin via LAT1. Thus, to understand the detailed mechanism of the transport system in therapeutics for CNS disorders across the BBB, further studies related to amino acid transport systems are required.

### Conclusions

Our results demonstrated that L-citrulline transport might be mainly mediated by LAT1 in TR-BBB cells. Understanding the transport characteristics of L-citrulline to the brain through BBB might contribute to the transport strategy for L-citrulline as a potential therapeutic agent for cerebrovascular diseases such as brain ischemia.

### Acknowledgements

The authors wish to thank Dr. Terasaki for providing TR-BBB cell lines. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2011-0030074).

### Availability of data and materials

All data generated or analyzed during this study are included in this published article.

### Authors’ contributions

KEL and YSK conceived and designed experiments. KEL performed experiments, collected, analyzed data, and wrote the manuscript. YSK contributed to data analysis and reviewed the manuscript. Both authors read and approved the final manuscript.

### Competing interests

The authors declare that they have no competing interests.

### Consent for publication

Not applicable.

### Ethics approval and consent to participate

Not applicable.

### Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Table 4 Effect of several drugs on uptake of $[^{14}C]$L-citrulline in TR-BBB cells

| Substrate    | Concentration (mM) | Uptake of $[^{14}C]$L-citrulline (% of control) |
|--------------|-------------------|-----------------------------------------------|
| Control      |                   | 100 ± 1.3                                     |
| L-Dopa       | 0.5               | 52.1 ± 6.6**                                  |
|              | 2                 | 21.6 ± 2.8***                                 |
| Gabapentin   | 0.5               | 45.0 ± 2.5***                                 |
|              | 5                 | 29.6 ± 2.73***                                |
| Verapamil    | 0.5               | 30.9 ± 0.3***                                 |
| Quinidine    | 0.5               | 52.5 ± 3.0***                                 |
| Dopamine     | 2                 | 110.5 ± 2.7                                   |
| Donepezil    | 2                 | 85.5 ± 5.9                                    |
| Riluzole     | 2                 | 93.9 ± 8.3                                    |
| Taurine      | 2                 | 90.5 ± 4.4                                    |

$[^{14}C]$L-citrulline uptake by TR-BBB cells was performed at pH7.4 and 37 °C for 5 min in the presence or absence (control) of 2 mM drugs (except for 500 μM quinidine, verapamil and 200 μM of riluzole). Each value represents the mean ± S.E.M. (n = 3–4). **p < 0.01, ***p < 0.001; significantly different from control.
References

1. Mandel H, Levy N, Iakovitch S, et al. Elevated plasma citrulline and arginine due to consumption of Citrullus vulgaris (watermelon). J Inherit Metab Dis. 2005;28:467–72.

2. Bahri S, Cursi E, El Wafi FZ, et al. Mechanisms and kinetics of citrulline uptake in a model of human intestinal epithelial cells. Clin Nutr. 2008;27:82–70.

3. Romero MJ, Platt DH, Caldwell RB, et al. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev. 2006;24:275–90.

4. Cycober L, Moirand C, De Bandt JP. Citrulline: a new major signaling molecule or just another player in the pharmacotherapy game? Clin Nutr. 2010;29:545–51.

5. Wu G. Intestinal mucosal amino acid catabolism. J Nutr. 1998;128(8):1249–52.

6. Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci. 2008;27:785–802.

7. Paul V, Ekambaram P. Involvement of nitric oxide in learning & memory processes. Indian J Med Res. 2011;133:471–8.

8. Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res. 1999;31(6):577–96.

9. Calabrese V, Mancuso C, Calvani M, et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci. 2007;8:766–75.

10. Zhou L, Zhu DY. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide. 2009;20(4):223–30.

11. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to amino acid transport in neural cell cultures. Dev Neurosci. 2000;22:393–403.

12. Liu DH, Yuan FG, Hu SQ, et al. Endogenous nitric oxide induces activation of apoptosis signal-regulating kinase 1 via S-nitrosylation in rat hippocampus during cerebral ischemia-reperfusion. Neurosci. 2013;229:36–48.

13. Yabuki Y, Shoda N, Yamamoto Y, et al. Oral -citrulline administration improves memory deficits following transient brain ischemia through cerebrovascular protection. Brain Res. 2013;1520:157–67.

14. Baydoun AR, Bogle RG, Pearson JD, et al. Discrimination between citrulline and arginine transport in activated murine macrophages: inefficient synthesis of NO from recycling of citrulline to arginine. Br J Pharmacol. 1994;112:487–92.

15. Wilken SM, Mann GE, Pearson JD, et al. Role of -citrulline transport in nitric oxide synthesis in rat aortic smooth muscle cells activated with LPS and interferon-gamma. Br J Pharmacol. 2003;140:179–85.

16. Schmidlin A, Fischer S, Wiesinger H. Transport of L-citrulline in neural cell cultures. Dev Neurosci. 2000;22:395–8.

17. Matsuoka K, Shirasaka Y, Fukushima A, et al. Transport characteristics of -citrulline in renal apical membrane of proximal tubular cells. Biopharm Drug Dispos. 2009;30:126–37.

18. Hosoya K, Takashima T, Tetsuka T, et al. mRNA expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines: a new in vitro BBB model for drug targeting. J Drug Target. 2009;17:57–70.

19. Kang YS, Ohtsuki S, Takagawa S, et al. Regulation of transport in the brain–blood barrier by tumor necrosis factor-alpha, tumour and hypoxicity. J Neurochem. 2002;83:188–95.

20. Nakamura N, Aoyagi K, et al. Functional characterization of rat plasma membrane monoamine transporter in the blood–brain barrier. Brain Res. 2000;879:115–20.

21. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood–brain barrier as a supporting and protecting interface for the brain: importance for CNS drug discovery and development. Pharmacol Res. 2007;56(4):1745–58.

22. Kuris E, Nicolis I, Moirand C, et al. Almost all about citrulline in mammals. Amino Acids. 2005;29:177–205.

23. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70(1):743–77.

24. Kim DK, Kanai Y, Matsuo H, et al. The human T type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics. 2002;79:95–103.

25. O’Kane RL, Vrha JR, Simpson L, et al. Cationic amino acid transport across the blood–brain barrier is mediated exclusively by system y+? Am J Physiol Endocrinol Metab. 2006;291:E412–9.

26. Boado RJ, Li JY, Nagaya M, et al. Selective expression of the large neutral amino acid transporter at the blood–brain barrier. Proc Natl Acad Sci U S A. 1999;96:12079–84.

27. Matsuho H, Tsukada S, Nakata T, et al. Expression of a system L neutral amino acid transporter at the blood–brain barrier. Neuroreport. 2000;11:3507–11.

28. Zhan X, Godf WM, Hsimaline attenuates voltage-sensitive Ca(2+) currents in neurons of the inferior olive. J Pharm Sci. 2012;115(5):567–68.

29. Terasaki T, Hosoya K. Conditionally immortalized cell lines as a new in vitro model for the study of barrier functions. Biol Pharm Bull. 2001;24(2):111–8.

30. Smith QR, Stoll J. Blood–brain barrier amino acid transport, Introduction to blood–brain barrier: methodology and pathology. Cambridge: Cambridge University Press. 1998. pp. 188–97.

31. del AMO EM, Urti A, Ylippertula M. Pharmacokinetic role of -type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci. 2008;35:161–74.

32. Moirand C, Nicolis I, Neveux N, et al. Dose-ranging effects of citrulline administration on plasma arginine and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. Br J Nutr. 2008;99:855–62.

33. Cycober L. Pharmacokinetics of arginine and related amino acids. J Nutr. 2007;137(6 Suppl 2):1693S–701.

34. Shen LJ, et al. Accessibility of endothelial and inducible nitric oxide synthase to the intracellular citrulline-arginine regeneration pathway. Biochem Pharmacol. 2005;69(1):197–104.

35. McNailly WP, Pool WF, Sinn MW, et al. Distribution of tarcine and metabolites in rat brain and plasma after single- and multiple-dose regiments. Evidence for accumulation of tarcine in brain tissue. Drug Metab Dispos. 1996;24(6):628–33.

36. Matsu K, Mishima M, Nagay Y, et al. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug Metab Dispos. 1999;27(1):1406–14.

37. Polinsky RJ. Clinical pharmacology of ravistigmine: a new-generation acetycholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther. 1998;20:34–47.

38. Kang YS, Lee KE, Lee NY, et al. Donepezil, tarcine and alpha-phenyl-n-tet-butyl nitroene (PBN) inhibit choline transport by conditionally immortalized rat brain capillary endothelial cell lines (TR-BBB). Arch Pharm Res. 2005;28:443–50.

39. Kim MH, Maenng HJ, Yu KH, et al. Evidence of carrier mediated transport in the penetration of donepezil into the rat brain. J Pharm Sci. 2009;99:1548–66.

40. Sung JH, Yu KH, Park JS, et al. Saturable distribution of tarcine into the striatal extracellular fluid of the rat: evidence of involvement of multiple organic cation transporters in the transport. Drug Metab Dispos. 2005;33:440–8.

41. Okura T, Kato S, Takano Y, et al. Functional characterization of rat plasma membrane monoamine transporter in the blood–brain and blood-cerebrospinal fluid barriers. J Pharm Sci. 2011;100:3024–38.

42. Brooks BR. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol. 2009;65(Suppl 1):S17–23.

43. Frizzo ME, Dall’Onder LP, Dalclin KB, et al. Riluzole enhances glutamate uptake in rat astrocytes cultures. Cell Mol Neurobiol. 2004;24:123–8.

44. Fumagalli E, Funicello M, Rauen T, et al. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharm Sci. 2008;37:171–6.

45. Kageyama T, Nakamura M, Matsuo A, et al. The 42hc/LAT1 complex transports -DOPA across the blood–brain barrier. Brain Res. 2000;879:115–21.

46. Dickens D, Webb SD, Antonyuk S, et al. Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol. 2013;85:1672–83.

47. Haust P, Johnston TH, Koprich JB, et al. -DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson’s disease. Neuropharmacol. 2012;63:829–36.

48. Carlsson KC, van de Schootbrugge M, Eriksen HO, et al. A population pharmacokinetic model of gabapentin developed in nonparametric, adaptive grid and nonlinear mixed effects modeling. Ther Drug Monit. 2009;31:86–94.